Existing evidence led us to hypothesize that increases in p85␣, a regulatory subunit of PI3-kinase, in presympathetic brain areas contribute to hypertension. PI3-kinase p85␣, p110␣, and p110␦ mRNA was 1.5-to 2-fold higher in the paraventricular nucleus (PVN) of spontaneously hypertensive rats (SHR) compared with their controls, Wistar Kyoto rats (WKY). The increase in p85␣/p110␦ was attenuated in SHR treated with captopril, an angiotensin (Ang)converting enzyme inhibitor, from in utero to 6 months of age. In the rostral ventrolateral medulla (RVLM), p110␦ mRNA was Ϸ2-fold higher in SHR than in WKY. Moreover, the increases in mRNA were associated with higher PI3-kinase activity in both nuclei. The functional relevance was studied in neuronal cultures because SHR neurons reflect the augmented p85␣ mRNA and PI3-kinase activity. Expression of a p85 dominant-negative mutant decreased norepinephrine (NE) transporter mRNA and [ 3 H]NE uptake by Ϸ60% selectively in SHR neurons. In summary, increased p85␣/p110␦ expression in the PVN and RVLM is associated with increased PI3-kinase activity in the SHR. Furthermore, normalized PI3-kinase p85␣/p110␦ expression within the PVN might contribute to the overall effect of captopril, perhaps attributable to a consequent decrease in NE availability. Circulation Research
P hosphoinositide 3-kinase (PI3-kinase) influences diverse physiological functions, 1 and increases in its activity has been linked to hypertension. 2, 3 Hypertension in experimental models, including the spontaneously hypertensive rat (SHR), is partly dependent on central nervous system angiotensin (Ang) II-mediated increases in sympathetic activity. 4 Furthermore, in brain areas that regulate sympathetic activity, increases in tyrosine hydroxylase, norepinephrine transporter (NET), and adrenergic ␣ 1A receptors parallel the development of hypertension in SHR, suggesting that enhanced adrenergic transmission contributes to hypertension. 5, 6 Our group demonstrated that PI3-kinase signaling mediates augmented Ang II-mediated norepinephrine (NE) neuromodulation in hypothalamus/brainstem SHR neuronal cultures. 7 In addition, PI3-kinase inhibition within the rostral ventrolateral medulla (RVLM), a major presympathetic area, decreases blood pressure (BP) of the SHR to levels similar to that of their normotensive controls, Wistar Kyoto rats (WKY). 2 Thus, it appears that a central PI3-kinase signaling pathway is critical for hypertension, possibly as a mediator of Ang II-induced NE neuromodulation.
Class I PI3-kinases consist of a catalytic subunit (p110␣, ␤, ␦, and ␥) and a regulatory subunit (p85␣ and its alternatively spliced forms, p85␤, p55␥, and p101). 1 Ang II stimulation results in prolonged increases in p85␣-associated PI3-kinase activity in SHR neurons, 7 indicating that the p110 isoforms that dimerize with p85␣ mediate this effect. Based on these findings, we hypothesized that increases in expression of p85␣ in presympathetic brain areas contribute to hypertension. Thus, our aims were to determine whether p85␣ expression is increased in presympathetic brain areas of SHR and to assess if this increase is normalized after angiotensinconverting enzyme inhibition. We focused on the RVLM and the paraventricular nucleus (PVN), a nucleus with substantial noradrenergic input, because altered Ang and NE mechanisms in these nuclei have been linked to hypertension. 4 -6,8 Materials and Methods PI3-kinase mRNA was assessed in PVN and RVLM micropunches of WKY, SHR, and SHR that received an angiotensin-converting enzyme inhibitor (captorpril, in utero to 6 months, 40 mg/L; 8 ). BP and cardiac and coronary artery hypertrophy were evaluated. 9 Primary neuronal cultures were derived from the hypothalamus/ brainstem of newborn SHR and WKY. 7 PI3-kinase activity 3 was assessed in micropunches and neuronal cultures. The cultures were infected with an adenoviral vector that expresses a p85 dominant-negative mutant 10 (Ad.⌬p85) or enhanced green fluorescent protein (Ad.eGFP). PI3-kinase protein, ⌬p85 expression, and phosphorylation (Ser 473) of Akt, a downstream effector of PI3-kinase, were determined. NET mRNA and maprotiline-sensitive [ 3 H]NE uptake 7 were measured 48 hours after adenoviral infection. An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Results
Early, long-term captopril treatment prevented hypertension and cardiac hypertrophy in SHR (supplemental Figure I and Table in the online data supplement), consistent with a previous report. 10
Increased PI3-Kinase Expression and Activity in Presympathetic Areas Is Associated With Hypertension
In the PVN, p85␣ mRNA was Ϸ60% higher in SHR than in WKY. This increase was prevented by captopril treatment ( Figure 1A ). However, p85␣ mRNA in the RVLM did not vary significantly between groups. Next, we assessed mRNA levels of PI3-kinase catalytic subunits that dimerize with p85␣. PI3-kinase p110␦ mRNA was increased in the PVN and RVLM of SHR compared with WKY, but only the increase in the PVN was prevented in the SHR group that received an angiotensin-converting enzyme inhibitor captorpril ( Figure 1C ). Whereas an increase in PI3-kinase p110␣ mRNA was noted in the PVN of SHR, it was not normalized after captopril treatment ( Figure 1B and 1C ). PI3-kinase p110␤ expression did not differ between groups (data not shown) and subunit expression did not vary between groups in the anterior hypothalamic area ( Figure II in the online data supplement). In SHR, p85␣-associated PI3-kinase activity was increased Ϸ2.5fold in the PVN ( Figure 1F ), but not in the RVLM (data not shown). However, p110␦-associated PI3-kinase activity was increased Ϸ1.5-fold in the SHR RVLM ( Figure 1F) . A significant increase in p85␣ mRNA and protein (Ϸ40%), but not PI3-kinase p110 subunits, was detected in neurons derived from prehypertensive SHR and was associated with increased PI3kinase activity ( Figure 1D to 1F). This suggests that the increased hypothalamic p85␣ expression and PI3-kinase activity in SHR is not secondary to hypertension.
Expression of ⌬p85 Decreases NE Uptake Selectively in SHR Neurons
We studied the effect of decreased p85/p110 association in neuronal cultures to determine the effect of decreased p85␣ on NE neuromodulation. Transduction with Ad.⌬p85 resulted in Ϸ10-fold increase in immunoreactive p85␣ protein and decreased Akt phosphorylation in WKY and SHR neurons compared with Ad.eGFP-infected controls ( Figure 2B ), establishing that ⌬p85 functioned as dominant-negative.
[ 3 H]NE uptake was 3-fold higher in Ad.eGFP-infected SHR compared with WKY neurons, consistent with increased NE neurotransmission in SHR neurons. 4 In addition, transduction with Ad.⌬p85 decreased NET mRNA and [ 3 H]NE uptake by 50% to 60% exclusively in SHR neurons ( Figure 2C and 2D) .
These results indicate that p85 expression is critical for NE uptake in SHR, with decreased p85/p110 association resulting in decreased NE neuromodulation.
Discussion
The present study provides the first direct evidence for increased PI3-kinase expression and activity within presympathetic brain areas of the SHR. Our findings suggest that normalized PI3-kinase p85␣/p110␦ expression within the PVN might contribute to the overall effect of captopril, possibly via modulation of NE availability. We demonstrate increased gene expression of p85␣, p110␣, and p110␦ in the PVN of SHR compared with WKY. In contrast, only p110␦ mRNA was increased in the SHR RVLM. Increased p85␣/spliced variant-associated PI3-kinase activity was detected in SHR PVN, but not in the RVLM. Because wortmanin inhibition of the RVLM decreases BP exclusively in SHR, 2 it would suggest that regulatory subunits other than p85␣ that associate with p110␦ are involved. We detected increased p110␦-associated PI3-kinase activity in the RVLM of SHR. Thus, our study indicates that increased p85␣/p110␣ and p85␣/p110␦ association in the PVN, and p110␦ association with p85␤/p55␥ in the RVLM, likely account for the increased PI3-kinase activity in SHR. In addition, p85␣ expression and its associated activity were increased in neuronal cultures derived from prehypertensive SHR. Furthermore, the increase in p85␣ appears to precede the increases in p110 expression as only p85␣ expression was increased in SHR cultures. Moreover, the increases in PI3kinase mRNA appear to be specific for presympathetic areas, because subunit expression was comparable between strains in the anterior hypothalamic area. Finally, a transient Ad.⌬p85 gene transfer in the PVN resulted in sustained decreases in heart rate in SHR, but not WKY, in preliminary experiments. Whereas a decrease in BP was not evident, it is likely that long-term expression of ⌬p85 may be required to reflect changes in BP. Thus, these data provide compelling evidence in support of our hypothesis that p85␣ expression, at least in the PVN, contributes to hypertension in the SHR.
Enhanced angiotensinergic mechanisms in the RVLM and PVN contribute to hypertension. The enhanced tonic sympatho-excitatory activity of RVLM vasomotor neurons in SHR is largely mediated by Ang type I (AT 1 ) receptor activation. 4 This is mainly attributable to an exaggerated tonic excitatory input to RVLM AT 1 receptors from the PVN. 4 Augmented noradrenergic mechanisms also contribute to hypertension. In the SHR RVLM, increases in tyrosine hydroxylase, NET, and adrenergic ␣1A receptors parallel the development of hypertension. 5, 6 In addition, NE synthesis appears to be enhanced in the PVN of SHR. 9 In cultured hypothalamus/ brainstem SHR neurons, Ang II stimulation results in augmented NE synthesis and uptake via PI3-kinase signaling. 7 Our findings of increased PI3-kinase subunit expression in the PVN and RVLM of SHR are consistent with increased NET expression in the SHR RVLM 6 and augmented Ang II signaling and NE neuromodulation mediated by p85␣/p110␦ in these areas.
Long-term captopril treatment prevented hypertension and normalized p85␣ and p110␦ expression in the PVN of SHR. We demonstrated a direct effect of decreased p85 function on NE neuromodulation in cultured SHR neurons. Disruption of endogenous p85/p110 association by ⌬p85 selectively decreased NET mRNA and NE uptake in SHR neurons, suggesting that normalized p85␣ expression in the PVN of SHR likely resulted in decreased NE neuromodulation. In addition, altered PI3-kinase signaling may have an indirect effect on NE neurons. Captopril treatment did not normalize RVLM p110␦ expression in SHR. This suggests that whereas PI3-kinase activity in the RVLM may contribute to maintaining hypertension, 2 decreases in PI3kinase activity within the RVLM are not required for the antihypertensive effect of captopril.
In conclusion, this study indicates that increased PI3-kinase subunit expression in the PVN and RVLM is associated with hypertension in the SHR. Furthermore, the effect of captopril treatment may be mediated by normalization of p85␣/p110␦ expression in the PVN and consequent NE neuromodulation. 
